Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Cancer stem cells (CSCs) exhibit enhanced chemo/radiotherapy resistance, and their survival following cancer treatment is believed to be responsible for tumor recurrence and metastasis. Thus, understanding the mechanisms through which CSCs survive conventional chemotherapy is essential for identification of new therapeutic strategies to prevent tumor relapse. Our findings that ovarian CSCs survive cisplatin treatment through elevated expression of polymerase η represent an opportunity to eradicate CSCs and improve the survival of ovarian cancer patients. In addition, identification of miR-93 as the regulator of polymerase η expression provides a target to increase the efficacy of cisplatin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, this DNA polymerase was shown to be induced in several human cell lines after treatment with chemotherapeutic agents in a p53-dependent manner, and was linked to acquired resistance to chemotherapy ( 24 , 25 ).”
From Predominant role of DNA polymerase eta and p53-dependent translesion synthesis in the survival of ultraviolet-irradiated human cells (2017) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The upregulation of miR-93, a microRNA that triggers pol η degradation, also enhanced the effect of cisplatin [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Experimental — accuracy not yet measuredIn the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells, which is evidenced in populations that resist cisplatin treatment [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The protective role of TLS in cancer is revealed by the overexpression of pol η in ovarian-cancer cells”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
In the citing paper
“The effect of cisplatin was enhanced when simultaneously depleting pol η in ovarian-cancer-cell models [110]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundDirect Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391 · cited 1×
“These cross-links block DNA replication and invoke apoptosis in rapidly dividing cells (5).”
BackgroundIdentification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293 · cited 15×
“Ovarian CSCs have been successfully isolated, based on the expression of distinctive cell surface markers CD44 and CD117 (18, 19), their ability to efflux the Hoechst 33342 fluorescent dye (Side population, SP) (20), the activity of ALDH (21), and their ability to grow as floating spheres in serum-free medium (19).”
BackgroundMethodInfluentialCancer Stem Cells: Models and Concepts
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.062105.204854 · Cited by 1,274 · cited 1×
“The CD44CD117 cells, SP cells, ALDH cells, and spheroid cells isolated from both ovarian cancer cell lines and primary human ovarian tumors fulfill all currently accepted criteria for the existence of a subpopulation of tumor-initiating cells (19, 22, 23).”
BackgroundCancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171 · cited 1×
“Thus, this reduced expression of MCM7, probably due to relative quiescence of CSCs (49, 50), could be a contributor to the decreased expression of miR-93 in CSCs.”
BackgroundOvarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154 · cited 2×
“Cancer Chemother Pharmacol 39(3):245–253.”
BackgroundSide Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3557 · Cited by 947 · cited 1×
“Although MCM7 overexpression has been identified in various tumors and considered a bad prognostic indicator in prostate cancer (45, 46), MCM7 expression is lower in various CSCs, including SP of human lung cancer cells (47) and prostate cancer cells (48), as well as ALDH+ breast cancer cells (41).”
BackgroundMechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869 · cited 6×
“Among many polymerases tested in vitro, the Y-family DNA Pol η is the most efficient and accurate at bypassing Pt-GG lesions (10, 37, 38).”
MethodInfluential
Cited by
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
“Srivastava found that enhanced expression of DNA polymerase contributes to cisplatin resistance in ovarian CSCs.(135) In contrast, pharmacological inhibition of the DNA damage checkpoints CHK1 and CHK2 sensitized CSCs to radiotherapy.”
BackgroundSelf-citationDNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
“A recent report showed elevated PolZ expression in ovarian cancer stem cells isolated from ovarian cancer cell lines and primary tumors (77).”
BackgroundAdvances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Vitale, I., Manic, G., De Maria, R., Kroemer, G., & Galluzzi, L. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.006 · Cited by 361
“Accordingly, genetic inhibition of POLH by small interfering RNAs (siRNAs) or microRNAs (miRNAs) reportedly sensitizes ovarian CSCs to the genotoxic effects of cisplatin, in vitro and in vivo (Srivastava et al., 2015) (Figure 2).”
BackgroundNon-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Cancer Stem Cells and Radioresistance: DNA Repair and Beyond
Schulz, A., Meyer, F., Dubrovska, A., & Borgmann, K. (2019) · Cancers · doi:10.3390/cancers11060862 · Cited by 303
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
“Its expression seems to be higher in cancer stem cells, thus possibly accounting for the intrinsic resistance this subpopulation has to cisplatin treatment [92,93].”
BackgroundDrug resistance in ovarian cancer: from mechanism to clinical trial
Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01967-3 · Cited by 255
“It increases the tolerance of tumor cells to plat-inum-induced DNA adducts and results in platinum resistance [92].”
BackgroundCancer stem cells: Road to therapeutic resistance and strategies to overcome resistance
Makena, M. R., Ranjan, A., Thirumala, V., & Reddy, A. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.015 · Cited by 166
Targeting Cancer Stem Cells to Overcome Chemoresistance
Nunes, T., Hamdan, D., Lebœuf, C., Bouchtaoui, M. E., Gapihan, G., Nguyen, T. T. N., Meles, S., Angeli, E., Ratajczak, P., Lu, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124036 · Cited by 164
Li, B., Wang, W., Li, Z., Chen, Z., Zhi, X., Xu, J., Li, Q., Wang, L., Huang, X., Wang, L., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.035 · Cited by 153
“Immunostaining of phospho-H2AX (yH2AX) and ELISA assay for DNA-CDDP adducts detection [28] were used to test whether miR-148a-3p facilitated CDDP sensitivity in GC cells through inhibiting the DNA damage repair process.”
MethodSelf-citationDNA damage response and resistance of cancer stem cells
Abad, E., Graifer, D., & Lyakhovich, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.008 · Cited by 153
Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism
Li, S., Ma, J., & Wong, A. S. T. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e32 · Cited by 152
“For example, polymerase η (Pol η) enhanced cisplatininduced apoptosis and blocked the cisplatin-induced enrichment of ovarian CSCs, suggesting that an increase in expression of DNA Pol η in CD44+/CD117+ contributes to drug resistance [39].”
BackgroundLeveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 153
Wang, L., Liu, X., Ren, Y., Zhang, J., Chen, J., Zhou, W., Guo, W., Wang, X., Chen, H., Li, M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.409 · Cited by 139
Self-citationmiR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling
Helou, R. E., Pinna, G., Cabaud, O., Wicinski, J., Bhajun, R., Guyon, L., Rioualen, C., Finetti, P., Gros, A., Mari, B. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.016 · Cited by 136
“Supportingour results, differentmembersof this cluster are known to downregulate the CSC population and balance CSC fate by inducing cell differentiation (Liu et al., 2012b; Cioffi et al., 2015; Srivastava et al., 2015).”
BackgroundThe Effect of Oxidative Phosphorylation on Cancer Drug Resistance
Zhao, Z., Mei, Y., Wang, Z., & He, W. (2022) · Cancers · doi:10.3390/cancers15010062 · Cited by 145
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
Deng, J., Wang, L., Chen, H., Hao, J., Ni, J., Chang, L., Duan, W., Graham, P., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9908 · Cited by 115
“Srivastava et al reported that an elevated expression of DNA polymerase η (Pol η) was observed in OCSCs isolated from both OC cell lines and primary tumors, and down-regulation of Pol η enhanced the cisplatin-induced apoptosis in CSCs both in vivo and in vitro [91], indicating that CSCs may have intrinsically enhanced…”
BackgroundCDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114
Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells
Rezayatmand, H., Razmkhah, M., & Razeghian‐Jahromi, I. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02856-6 · Cited by 125
“Overexpression of polymerase η gives CSCs resistance to cisplatin in ovarian cancer cells, and sensitivity of CSCs to cisplatin is increased by activating mir-93, which regulates the expression of polymerase η [132].”
BackgroundSun, X., Li, Y., Zheng, M., Zuo, W., & Zheng, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162754 · Cited by 109
“In addition, miRNA dysregulation in CSCs is one of many factors responsible for cancer treatment failure [23,24].”
BackgroundDNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies
Wang, Q. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.57 · Cited by 99
Self-citationInhibition of miR-328–3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer
Srivastava, A. K., Banerjee, A. T., Cui, T., Han, C., Cai, S., Liu, L., Wu, D., Cui, R., Li, Z., Zhang, X., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3668 · Cited by 90
“Tumor cells were isolated, and putative CSCs were enriched as described in our previous work (17).”
BackgroundSelf-citationInhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
“Likewise depletion of REV3 in cervical cancer cells [109] or nonsmall cell lung cancer cells [110]; REV1, POL z, POL η in HeLa cells [111]; and POL η in ovarian cancer stem cells [39] all sensitize cells to cisplatin.”
BackgroundTGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 81
“Several molecular mechanisms have been proposed for resistance acquisition by CSCs such as autophagy for survival by recycling metabolites [234], high expression of ATP-binding cassette (ABC) transporters to increase drug efflux [235, 236] and increased DNA polymerase η (Pol η) synthesis to compensate for drug induced…”
BackgroundEffects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies
Mantso, T., Goussetis, G., Franco, R., Botaitis, S., Pappa, A., & Panayiotidis, M. I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.004 · Cited by 87
“CSCs thus implying the involvement of a Polε-mediated TLS which seems to contribute to their observed resistance in cisplatin treatment [87].”
Regulatory players of DNA damage repair mechanisms: Role in Cancer Chemoresistance
Sakthivel, K. M., & Hariharan, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.035 · Cited by 83
“treating the ovarian cancer stem cells with miR-93 reduces the expression of DNA polymerase eta and is associated with decreased chemoresistance [31].”
BackgroundPoli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 84
“Moreover, ovarian CSCs are characterized by enhanced expression of DNA polymerase eta, which ensures high tolerance to DNA damage [144].”
BackgroundIslam, S. S., & Aboussekhra, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1360-3 · Cited by 79
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Anand, J. R., Chiou, L. F., Sciandra, C. A., Zhang, X., Hong, J., Wu, D., Zhou, P., & Vaziri, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad005 · Cited by 83
“Pol expression and activity is elevated in cancer stem cells (CSC), the rare progenitors that both self-renew, repopulate tumors and account for chemoresistance (194).”
BackgroundSelf-citationInvolvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair
Roy, U., & Schärer, O. D. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.05.004 · Cited by 76
“Elevated levels of Pol η and Pol ζ were correlated with resistance to cisplatin treatment in ovarian cancer stem cells and cervical cancer cells, respectively [79, 80].”
BackgroundTargeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 79
Curcumin effect on cancer cells' multidrug resistance: An update
Keyvani‐Ghamsari, S., Khorsandi, K., & Gul, A. (2020) · Phytotherapy Research · doi:10.1002/ptr.6703 · Cited by 77
“Reprinted with permission from Rocha et al. (2018) [Colour figure can be viewed at wileyonlinelibrary.com] ovarian cancer stem cells (CSCs) to cisplatin so that downregulation of Pol η increased apoptosis in cells treated with cisplatin (Srivastava et al., 2015).”
BackgroundSalinomycin, as an autophagy modulator-- a new avenue to anticancer: a review
Jiang, J., Li, H., Qaed, E., Zhang, J., Song, Y., Wu, R., Bu, X.-M., Wang, Q., & Tang, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0680-z · Cited by 77
“Conventional chemotherapeutical drugs cannot efficiently kill CSCs, which led to the recurrence of the cancer [4, 33, 34].”
BackgroundSelf-citationSNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway
Zhu, W., Niu, J., He, M., Zhang, L., Lv, X., Liu, F., Jiang, L., Zhang, J., Yu, Z., Zhao, L., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2005-1 · Cited by 71
Alizadeh, H., Akbarabadi, P., Dadfar, A., Tareh, M. R., & Soltani, B. M. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02345-3 · Cited by 93
“The 3 ′ -UTR of Pol η mRNA is targeted by miR-93 , and reduced miR-93 increases Pol η expression, enhancing OCSC survival [65].”
Targeting the tumour microenvironment in platinum-resistant ovarian cancer
Cummings, M., Freer, C., & Orsi, N. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.007 · Cited by 69
Novel Therapeutic Strategies for Ovarian Cancer Stem Cells
Terraneo, N., Jacob, F., Dubrovska, A., & Grünberg, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00319 · Cited by 68
“Different populations of OC CSCs have a high resistance to the platinum agents due to the altered regulation of cell cycle checkpoint, upregulation of the Fanconi Anemia DNA repair proteins (FANCD2, FANCJ) (133), MLH1, and BRCA1 (134) and increased expression of DNA polymerase eta (135).”
BackgroundPeng, C., Chen, Z., Wang, S., Wang, H., Qiu, W., Zhao, L., Xu, R., Luo, H., Chen, D., Chen, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1884 · Cited by 79
The emerging roles of the polycistronic miR-106b∼25 cluster in cancer – A comprehensive review
Mehlich, D., Garbicz, F., & Wlodarski, P. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.097 · Cited by 71
Zhan, M., Zhao, X., Wang, H., Chen, W., Xu, S., Wang, W., Shen, H., Huang, S., & Wang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4957-6 · Cited by 63
“Recent discoveries have found that multiple regulators are involved in increasing cancer cell chemoresistance, including enhancement of DNA repair [7], inefficient cellular drug uptake and accumulation [8], activation of the antioxidant glutathione system for detoxification [9], upregulation of the antiapoptosis pathw…”
BackgroundXie, Q. M., Wang, S., Zhao, Y., Zhang, Z., Qin, C., & Yang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15781 · Cited by 62
“Although the drug-resistance is a major challenge for the cisplatin-treatment to the CSCs [34], the strategy for overexpressing the miR-519d may be a potential approach to increase the sensitivity of BCSCs to cisplatin.”
BackgroundCisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives
Lobo, J., Jerónimo, C., & Henrique, R. (2020) · Cancers · doi:10.3390/cancers12061601 · Cited by 64
“Man studies have focused on the various DNA repair systems, as the cisplatin resistant phenotype is shown to gain the ability to repair DNA lesions more proficiently and faster [68] or, alternatively, is able to tolerate such lesions by the upregulation of specific polymerases that bypass DNA adducts [69]—both ways no…”
BackgroundOvarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance
Mihanfar, A., Aghazadeh-Attari, J., Mohebbi, I., Majidinia, M., Kaviani, M., Yousefi, M., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26768 · Cited by 62
“A different mechanism was introduced in a study by Srivastava et al. (2015); they reported that an increased expression of DNA polymerase η (Pol η) was detected in OV‐CSCs isolated from both ovarian cancer cell lines and primary tumors.”
BackgroundLerner, L. K., Francisco, G., Soltys, D. T., Rocha, C. R. R., Quinet, A., Vessoni, A. T., Castro, L. P., David, T. I. P., Bustos, S. O., Strauss, B. E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1196 · Cited by 53
“Recently, this DNA polymerase was shown to be induced in several human cell lines after treatment with chemotherapeutic agents in a p53dependent manner, and was linked to acquired resistance to chemotherapy (24,25).”
Polη O-GlcNAcylation governs genome integrity during translesion DNA synthesis
Ma, X., Liu, H., Li, J., Wang, Y., Ding, Y., Shen, H., Yang, Y., Sun, C., Huang, M., Tu, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02164-1 · Cited by 56
A PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance
Zhang, J., Sun, W., Ren, C., Kong, X., Yan, W., & Chen, X. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3928 · Cited by 56
“Furthermore, a recent study found that enhanced expression of PolH is associated with cisplatin resistance by ovarian cancer stem cells [1].”
BackgroundVerona, F., Bella, S. D., Schirano, R., Manfredi, C., Angeloro, F., Bozzari, G., Todaro, M., Giannini, G., Stassi, G., & Veschi, V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529847 · Cited by 56
“…Non-Receptor Tyrosine Kinase; CD155, cluster of differentiation 155; MIF, macrophage inhibitory factor; NSCLC, Non-Small Cell Lung Cancer; CD47, cluster of differentiation 47; MEK1-2, MAPK/ERK Kinase 1-2; AKT1, AKT serine/threonine kinase 1; 5-FU, 5-fl uorouracil; ID1, Inhibitor of DNA Binding 1.”
Giudice, E., Huang, T., Nair, J. R., Zurcher, G., McCoy, A., Nousome, D., Radke, M. R., Swisher, E. M., Lipkowitz, S., Ibanez, K. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47215-6 · Cited by 51
“Polymerase eta and beta inhibition were shown to re-sensitize ovarian cancer cells to platinum agents 62,63 , and the polymerase theta inhibitor novobiocin appeared to be synthetically lethal with PARPi in in vitro and in vivo models 64,65 .”
Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities
Zafar, M. K., & Eoff, R. L. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00157 · Cited by 53
Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
Indini, A., Nigro, O., Lengyel, C. G., Ghidini, M., Petrillo, A., Lopez, S., Raspagliesi, F., Trapani, D., Khakoo, S. S., & Bogani, G. (2021) · Cancers · doi:10.3390/cancers13071663 · Cited by 49
miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance
Samuel, P., Pink, R. C., Brooks, S. A., & Carter, D. R. F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1121107 · Cited by 47
“[91,92] In the context of ovarian cancer, downregulation of miR-93 [41] and miR-96 [42] can allow the upregulation of POLH (also known as Pol η) and REV1, respectively, leading to greater capacity for translesion synthesis and thus greater resistance to cisplatin.”
BackgroundInfluentialGenna, V., Gaspari, R., Peraro, M. D., & Vivo, M. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw128 · Cited by 46
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
Skowron, M. A., Melnikova, M., van Roermund, J. G. H., Romano, A., Albers, P., Thomale, J., Schulz, W. A., Niegisch, G., & Hoffmann, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020590 · Cited by 44
Replication stress response in cancer stem cells as a target for chemotherapy
Manic, G., Sistigu, A., Corradi, F., Musella, M., Maria, R. D., & Vitale, I. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.003 · Cited by 43
Human DNA polymerase η accommodates RNA for strand extension
Su, Y. R., Egli, M., & Guengerich, F. P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809723 · Cited by 43
Filling gaps in translesion DNA synthesis in human cells
Quinet, A., Lerner, L. K., Martins, D. J., & Menck, C. F. M. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.02.004 · Cited by 48
The anti-tumor effect and bioactive phytochemicals of Hedyotis diffusa willd on ovarian cancer cells
Zhang, L., Zhang, J., Qi, B., Jiang, G., Liu, J., Zhang, P., Ma, Y., & Li, W. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.07.027 · Cited by 40
DNA polymerase eta: A potential pharmacological target for cancer therapy
Saha, P., Mandal, T., Talukdar, A. D., Kumar, D., Kumar, S., Tripathi, P. P., Wang, Q., & Srivastava, A. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30155 · Cited by 45
“Overexpression of miR‐93 facilitates downregulation of Pol η and sensitizes CSCs to Pt‐based drug treatment (Srivastava et al., 2015; Srivastava & Wang, 2016).”
BackgroundMethodInfluentialSelf-citationBarnes, R. P., Tsao, W.-C., Moldovan, G., & Eckert, K. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3931 · Cited by 39
Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment
Sekhar, K. R., & Freeman, M. L. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3631 · Cited by 39
Tanaka, N., Katayama, S., Reddy, A. K., Nishimura, K., Niwa, N., Hongo, H., Ogihara, K., Kosaka, T., Mizuno, R., Kikuchi, E., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1828 · Cited by 41
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 41
Bostian, A. C. L., Maddukuri, L., Reed, M. R., Savenka, T., Hartman, J. H., Davis, L., Pouncey, D. L., Miller, G. P., & Eoff, R. L. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00452 · Cited by 40
Regulation of translesion DNA synthesis in mammalian cells
Ma, X., Tang, T., & Guo, C. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22359 · Cited by 41
DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target
Ler, A. A. L., & Carty, M. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.822500 · Cited by 42
Zafar, M. K., Maddukuri, L., Ketkar, A. D., Penthala, N. R., Reed, M. R., Eddy, S., Crooks, P. A., & Eoff, R. L. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01176 · Cited by 40
In crystallo observation of three metal ion promoted DNA polymerase misincorporation
Chang, C., Luo, C. L., & Gao, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-30005-3 · Cited by 36
Hadjadj, D., Kim, S.-J., Denecker, T., Driss, L. B., Cadoret, J., Maric, C. A., Baldacci, G., & Fauchereau, F. (2017) · Aging · doi:10.18632/aging.101356 · Cited by 38
The Catalytic Mechanism of DNA and RNA Polymerases
Genna, V., Donati, E., & Vivo, M. D. (2018) · ACS Catalysis · doi:10.1021/acscatal.8b03363 · Cited by 36
Xu, J., Su, Q., Gao, M., Liang, Q., Li, J., & Chen, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s211125 · Cited by 36
“27 In breast cancer tumors, a distinct CSC population that potentially causes chemoresistance has been identi fi ed and implicated in the clonal evolution and expansion of cancer stem-like cells.”
BackgroundMentegari, E., Crespan, E., Bavagnoli, L., Kiššová, M., Bertoletti, F., Sabbioneda, S., Imhof, R., Sturla, S. J., Nilforoushan, A., Hübscher, U., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1275 · Cited by 44
“In cancer cells, Pol overexpression is induced by cis-Pt treatment and its levels correlate with chemoresistance and poor clinical outcomes of several tumors, such as non-small-lung or ovarian cancers (44,45).”
Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.
Yu, X., Zheng, H., Chan, M. T. V., & Wu, W. K. K. (2017) · Europe PMC (PubMed Central) · Cited by 34
RNA-splicing factor SART3 regulates translesion DNA synthesis
Huang, M., Zhou, B. O., Gong, J., Xing, L., Ma, X., Wang, F., Wu, W. J., Shen, H., Sun, C., Zhu, X., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky220 · Cited by 39
“Given that Pol can protect tumor cells from cisplatin treatment (50), the function of SART3 in these tumor cells might also contribute to cisplatin chemoresistance.”
BackgroundRoy, U., Mukherjee, S., Sharma, A., Frank, E. G., & Schärer, O. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw485 · Cited by 31
“However, pol deficiency also causes sensitivity to crosslinking agents (22–24) and pol upregulation in tumors is associated with resistance to treatment with cisplatin and nitrogen mustards (15,34).”
BackgroundVillafañez, F., García, I. A., Carbajosa, S., Pansa, M. F., Mansilla, S., Llorens, M. C., Angiolini, V., Guantay, L., Jacobs, H., Madauss, K. P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0724-7 · Cited by 30
Sakurai, Y., Ichinoe, M., Yoshida, K., Nakazato, Y., Saito, S., Satoh, M., Nakada, N., Sanoyama, I., Umezawa, A., Numata, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.001 · Cited by 31
Role of Translesion DNA Synthesis in the Metabolism of Replication-associated Nascent Strand Gaps
Khatib, J. B., Nicolae, C. M., & Moldovan, G. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168275 · Cited by 31
Platinum-resistant ovarian cancer: From mechanisms to treatment strategies
Li, H., Sheng, J.-J., Zheng, S. L., Liu, P.-W., Wu, N., Zeng, W., Li, Y., & Wang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101801 · Cited by 42
“It has been demonstrated that the intrinsically enhanced Pol η -medi- ated TLS in ovarian cancer stem cells (CSCs) might be one of the causes for the chemoresistance traits exhibited by CSCs. 96 Moreover, the function of tyrosine-derived fuma-rate in modulating TLS and chemosensitivity in EOC has been uncovered.”
Recently identified drug resistance biomarkers in ovarian cancer
Davidson, B. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156532 · Cited by 30
“Polη was further shown to be negatively regulated by miR-93 [84].”
BackgroundJin, M. L., Liu, Y., & Jeong, K. W. (2022) · Theranostics · doi:10.7150/thno.72599 · Cited by 28
“depletion of SETD1A resulted in the downregulation of all DNA replication and ubiquitination-related genes in TamR-CSCs, which participate in the maintenance of CSC stemness [48, 49] (Figure 7F).”
BackgroundReactive Oxygen Species-Mediated Autophagy Defines the Fate of Cancer Stem Cells
LLeonart, M. E., Abad, E., Graifer, D., & Lyakhovich, A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7223 · Cited by 27
“Moreover, an elevated expression of DNA polymerase g in ovarian CSCs (128), IL-6 signaling in lung CSCs (21), activation of Chk1 in nonsmall-cell lung cancer (8), and involvement of a membrane protein Caveolin-1 (79) have been reported among DDR mechanisms that are active in CSCs.”
Ju, X., Yu, H., Liang, D., Jiang, T., Liu, Y., Chen, L., Dong, Q., & Liu, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.092 · Cited by 26
MicroRNA-93 mediates cabergoline resistance by targeting ATG7 in prolactinoma
Wu, Z., Cai, L., Lu, J., Wang, C., Guan, J., Chen, X., Wu, J., Zheng, W., Wu, Z. B., Li, Q., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0203 · Cited by 26
Current updates on microRNAs as regulators of chemoresistance
Çalışkan, M., Güler, H., & Çetintaş, V. B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.084 · Cited by 24
Barnes, R. P., & Eckert, K. A. (2017) · Genes · doi:10.3390/genes8010019 · Cited by 27
“[72], POLK transcript was not affected even though miR-20b was downregulated in the ovarian cancer cells, and a miR-20b mimic did not alter Pol η expression [72].”
BackgroundMethodInhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
Choi, J.-S., Kim, S., Motea, E. A., & Berdis, A. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17254 · Cited by 25
“In vitro approaches measured the kinetic parameters, kcat, Km, and kcat/Km, for the utilization of dATP and 3-Eth-5-NITP by pol δ, the highfidelity polymerase involved in chromosomal replication and pol η, a specialized DNA polymerase that produces drug resistance by replicating damaged DNA [16, 17].”
BackgroundSumiyoshi, M., Soda, H., Sadanaga, N., Taniguchi, H., Ikeda, T., Maruta, H., Dotsu, Y., Ogawara, D., Fukuda, Y., & Mukae, H. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7866 · Cited by 25
“Ovarian cancer cells with small interfering RNA-induced knockdown of POLH encoding DNA polymerase η exhibit high sensitivity to CDDP (5).”
BackgroundRoshini, A., Lee, J., Bayarsaikhan, D., Kwak, P., Son, M., Byun, K., Salekdeh, G. H., & Lee, B. (2017) · Oncotarget · doi:10.18632/oncotarget.23703 · Cited by 22
Wilson, K. A., Fernandes, P. A., Ramos, M. J., & Wetmore, S. D. (2019) · ACS Catalysis · doi:10.1021/acscatal.8b04889 · Cited by 23
Gallo, D., & Brown, G. W. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1651817 · Cited by 23
“Down regulation of Pol g in ovarian cancer stem cells expressing high levels of Pol g increased cisplatin sensitivity (Srivastava et al. 2015) and human fibroblast cells deficient for Pol g are more sensitive to cisplatin, araC, and gemcitabine (Chen et al. 2006).”
BackgroundChen, C.-Y., Kawasumi, M., Lan, T.-Y., Poon, C.-L., Lin, Y.-S., Wu, P.-J., Chen, Y.-C., Chen, B., Wu, C., Lo, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010355 · Cited by 24
“Polymerase η has been characterized as a specialized DNA polymerase capable of replicating across ultraviolet- or cisplatin-induced DNA damage to prevent cell-cycle arrest [61–66], and a high level of polymerase η expression is correlated with poor prognosis among patients with platinum-based treatment of multiple can…”
BackgroundHeitmeir, B., Deniz, M., Janni, W., Rack, B. K., Schochter, F., & Wiesmüller, L. (2022) · Cancers · doi:10.3390/cancers14040997 · Cited by 23
Mechanisms used by cancer cells to tolerate drug-induced replication stress
Segeren, H. A., & Westendorp, B. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215804 · Cited by 23
Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Schwarzenbach, H., & Gahan, P. B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.010 · Cited by 29
Ketkar, A. D., Maddukuri, L., Penthala, N. R., Reed, M. R., Zafar, M. K., Crooks, P. A., & Eoff, R. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00304 · Cited by 22
Fork Protection and Therapy Resistance in Hereditary Breast Cancer
Cantor, S. B., & Calvo, J. A. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.034413 · Cited by 22
“2017) given the growing body of evidence illustrating a causative role for TLS in the development of chemoresistance (Doles et al. 2010; Xie et al. 2010b; Srivastava et al. 2015).”
BackgroundKodavati, M. M., Peroumal, D., & Acharya, N. (2018) · Molecular Microbiology · doi:10.1111/mmi.14004 · Cited by 22
“© 2018 John Wiley & Sons Ltd, Molecular Microbiology, 110, 707–727 Structural and biochemical evidence report that successful by-pass of cisplatin adducts by Polη allows continuous proliferation of cancer cells in the presence of the drugs (Ummat et al., 2012; Zhao et al., 2012; Srivastava et al., 2015).”
BackgroundMethodTsai, R. Y. L. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2152-y · Cited by 22
Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies
Very, N., & Yazidi‐Belkoura, I. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960312 · Cited by 20
“TLS process is believed to contribute to the development of cisplatin resistance (95).”
Background
Metadata
- Authors
- Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E.
- Affiliations
- Department of Radiology,
- Department of Molecular Virology, Immunology and Medical Genetics,
- Comprehensive Cancer Center,
- Department of Pathology,
- Center for Biostatistics, and
- The Ohio State University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-03-23
- Volume
- 112
- Issue
- 14
- Pages
- 4411-4416
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4394248
- OpenAlex
- W2035233698
- Cited by
- 188
- References
- 51
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 18 · 2022: 16 · 2021: 14 · 2020: 22 · 2019: 18 · 2018: 23 · 2017: 20 · 2016: 20 · 2015: 7
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Health (CA151248)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- DNA polymerase eta, cisplatin resistance, ovarian cancer stem cells, translesion synthesis, chemoresistance, miR-93, apoptosis, tumor recurrence, DNA damage response
- MeSH terms
- Y-Family DNA Polymerases, Animals, Cell Survival, Cisplatin, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, Female, Flow Cytometry, Humans, Mice, Nude, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Transplantation, Ovarian Neoplasms, Recurrence, Neoplastic Stem Cells, Down-Regulation, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.